- News & Events
- Stock Information
- Financial & Filings
- Investor Resources
Erik Holmlin is a dynamic leader with more than two decades of experience developing innovative solutions and companies in the life sciences and health care industries.
Erik’s experience includes positions at GenVault Corporation (CEO), Exiqon A/S (CCO) and Becton Dickinson (vice president of marketing and development). In 2001, Erik led the formation and financing efforts of GeneOhm Sciences, Inc. and orchestrated the company’s acquisition by Becton Dickinson in 2006. He also served as an entrepreneur in residence (EIR) at leading life-science venture capital firm Domain Associates, LLC.
Erik was a National Institutes of Health postdoctoral fellow at Harvard University and a National Science Foundation predoctoral fellow at the California Institute of Technology, Pasadena (Caltech). He holds a PhD in chemistry from Caltech and MBAs from UC Berkeley and Columbia University.
Christopher Stewart is a seasoned leader with over 20 years of experience spanning finance, accounting, and strategic planning for many commercial-stage operating businesses.
Chris has served in a number of executive roles in both private and public companies as Controller, V.P. of Finance and CFO. He also has experience with major financing events, acquisitions, and scaling revenues in high-growth tech companies. He joined Bionano from Tesla, where he served as Head of the Maxwell Ultracapacitors business unit after Maxwell Technology was acquired by Tesla. Chris received his Master of Science in Business Administration and Finance from University of Southern California and his MBA in Finance from Carnegie Mellon University.
Mark Oldakowski has a 20-year history of success in the development of systems for the life sciences and medical device industries.
Prior to joining Bionano Genomics, Mark led a global team at Brooks Life Science Systems in the development of sample analyzers, high-throughput screening solutions, and chemical storage and biobank systems. Prior to his time at Brooks, Mark was with Affymetrix, where he launched the array platform that is widely used today for GWAS and other genomics applications. Mark also spent time at Siemens Healthcare Diagnostics on the development of equipment for diagnostic core labs. During his 13 years at Life Technologies (formerly Applied Biosystems) he held various levels of responsibility in the development of systems for real-time PCR, sequencing and sample preparation. Mark holds a bachelor’s degree in electrical engineering and a master’s degree in computer and systems engineering from Rensselaer Polytechnic Institute in New York.
Richard joined Bionano as Chief Business Officer in June 2021. Richard has over two decades of experience in life sciences, focused on healthcare.
He co-founded and led commercial operations at Cradle Genomics, which is the leader in developing non-invasive prenatal tests based on analysis of intact cells. Prior to Cradle, he was the Senior Director of Strategic Product Marketing in Reproductive and Genetic Health at Illumina, where he led the product strategy and management for preimplantation testing, prenatal testing, chromosomal microarray (CMA) and postnatal genetic disease testing. As a Senior Director of Product Marketing at Affymetrix, he partnered with the global cytogenomics community to launch CytoScan, the market leading CMA product and the only FDA cleared whole genome copy number analysis platform. He also oversaw the launch of OncoScan for solid tumor analysis.
Jason joined Bionano as Chief Commercial Officer in June 2021. Jason’s experience includes sales in genetic diseases and cancer testing as well as pharmaceutical sales.
After time with Forest Laboratories as a pharmaceutical detailer, he was selected for sales leadership positions at GeneDx, Sema4 and PerkinElmer Genomics with responsibilities covering sales, marketing, customer support and managed care across North America, Europe, China and India. Under his leadership, GeneDx’s revenue grew from $8M to over $225M across a menu of genetic testing products. He has worked closely with major health insurance carriers to obtain coverage and to maximize reimbursement for testing and he launched Sema4’s commercial business. He was recruited to PerkinElmer Genomics to lead full global commercial scale up of their business and presided over growing revenues to significant levels in a short period of time. His experience in building and managing global commercial organizations and his proven track record of stellar results allow him to lead Bionano’s efforts to expand and accelerate growth of its business.
Alka Chaubey is double board-certified in clinical cytogenetics/genomics and clinical molecular genetics/genomics by the American Board of Medical Genetics and Genomics (ABMGG).
Previously, she was the Head of Cytogenomics at PerkinElmer Genomics, where Dr. Chaubey led the successful development and launch of several innovative products including the CNGnome test (low-pass whole genome sequencing), and a new FSHD assay utilizing Saphyr. She has also played an integral role on Vanadis team at PerkinElmer in their efforts to bring a new PCR-free NIPT technology to the market. Prior to PerkinElmer Genomics, Dr. Chaubey was the Director of the Cytogenomics Laboratory at the Greenwood Genetic Center, SC, USA. She also holds an academic appointment as the Scientific Director of the Georgia Esoteric and Molecular Laboratory, Scientific Director of the Cytogenetics Laboratory of the Augusta University Medical Center and Adjunct Assistant professor of Pathology of the medical College of Georgia at Augusta University.